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ABSTRACT 
Objective: To develop an innovative, rapid, simple, cost-effective, stability indicating reverse phase-high performance liquid chromatography (RP-
HPLC) method for simultaneous estimation of ledipasvir (LP) and sofosbuvir (SB) in combination pill dosage form. 
Methods: The method was developed using C8 column, 250 mm x 4.6 mm, 5 mm using mobile section comprising of 0.1% (v/v) orthophosphoric 
acid buffer at pH 2.2 and acetonitrile in the ratio of 45:55 that was pumped through the column at a flow rate of 0.8 ml/min. Temperature was 
maintained at 30 °C, the effluents were monitored at 260 nm with the help of usage of PDA detector. 
Results: The retention time of LP and SB were found to be 2.246 min and 3.502 min. The approach was found to be linear with the variety of 9-36 
µg/ml and 40-240 μg/ml for LP and SB respectively, the assay of estimated compounds were found to be 99.65% and 99.73% w/v for LP and SB 
respectively. 
Conclusion: The pressured samples changed into analyzed and this proposed a technique turned into determined to be particular and stability 
indicating as no interfering peaks of decay compound and excipients were observed. Hence, the approach was easy and economical that may be 
efficiently applied for simultaneous estimation of both LP and SB in bulk and combination tablet system. 
Keywords: Ledipasvir, Sofosbuvir, Assay, ICH guidelines, Force degradation 




Various drugs are used for the treatment of ailments, but sometimes 
multiple drug therapy is being followed for cure of chronic disease, 
as well as it has better patient acceptability due to reduced number 
of dosage forms to be taken at a time [1-3]. Several optimization 
techniques are also employed using various latest experimental 
designs for the latest innovations in developmental methods [4]. In 
the present work we are trying to develop a method for combination 
of ledipasvir (LP) and sofosbuvir (SB) by RP-HPLC technique [5]. 




yl]carbamate. LP is a direct-acting antiviral medication used as part 
of combination therapy to treat chronic hepatitis c, an infectious 
liver disease caused by infection with (HCV). LP inhibits an 
important viral phosphoprotein, NS5A, which is involved in viral 
replication, assembly, and secretion. 
SB chemically comprises of propan-2-yl (2S)-2-{[(S)-{[(2R,3R,4R,5R)-
5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-4-fluoro-3-hydroxy-4-
methyloxolan-2-yl]methoxy} (phenoxy) phosphoryl] amino} 
propanoate. Treatment options for chronic Hepatitis C have 
advanced significantly since 2011, with the development of direct-
acting antivirals such as sofosbuvir. SB is a nucleotide analog 
inhibitor, which specifically inhibits HCV NS5B (non-structural 
protein 5B) rna-dependent rna polymerase. The broad writing study 
uncovered that RP-HPLC [6-14] and UV spectrophotometric 
techniques [15-17] and UPLC strategies were accessible for the 
assurance of LP and SB separately or in mix with different 
medications. The investigation performed with a plan to build up a 
straightforward, financial, touchy, quick, exact, and steadiness 
demonstrating RP-HPLC technique for the assurance of ledipasvir 
and sofosbuvir in joined tablet measurements shape. 
 
Fig. 1: Structure of ledipasvir 
 
 
Fig. 2: Structure of sofosbuvir 
 
MATERIALS AND METHODS 
Instruments: Waters (2695) PDA detector HPLC using the software 
Empower 2.  
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Chemicals and reagent 
Material Source 
Reference sample Spectrum pharma labs, 
Hyderabad, Telangana 
Test sample (LediHep 
Formulation) 
Local pharmacy 
HPLC grade: acetonitrile, 
methanol, and water 
Merck chemical division, 
Mumbai 
Potassium dihydrogen ortho 
phosphate, ortho-phosphoric acid 
Rankem  
 
Preparation of mobile phase 
(0.1% v/v, opa buffer) 1 ml of orthophosphoric acid solution in a 
1000 ml of volumetric flask add about 100 ml of milli-Q water and 
final volume make up to mark with milli-Q water at pH 2.2 and 
acetonitrile (45:55 v/v). 
Preparation of standard solutions 
Accurately weighed and transferred 9 mg of LP and 40 mg of SB 
working standards into a 25 ml and 25 ml clean dry volumetric 
flasks, add 10 ml of diluent, sonicated for 10 min and makeup to the 
final volume with diluents.  
Preparation of sample solution 
5 tablets (LediHep) were weighed and the average weight of each 
tablet was calculated, then the weight equivalent to 1 tablet was 
transferred into a 50 ml volumetric flask, 20 ml of diluents was 
added and sonicated for 25 min, further the volume was made up 
with diluent and filtered by HPLC filters (360µg/ml of LP and 
1600µg/ml of SB). 
Chromatographic conditions 
The chromatographic column used was discovery C8 250 mm x 4.6 
mm, 5 µm. The flow rate was maintained at 0.8 ml/min. The 
detection wavelength was 260 nm. The temperature was at 30 °C. 
The injection volume was 10 μl. The run time of standard and 
sample was 7 min.  
Optimization of RP-HPLC method 
The HPLC method was optimized with an aim to develop a 
simultaneous estimation procedure for the assay of LP and SB. For 
optimization of method, different mobile phases were tried, but 
acceptable retention times, theoretical plates and good resolution 
were observed with 0.1% opa buffer at pH 2.2 and acetonitrile 
(45:55 v/v) using column discovery C8 (250 mm x 4.6 mm, 5 
µm),The results were shown in fig. 3.  
Validation of the RP-HPLC method 
Validation of the optimized method was performed according to the 
ICH guidelines [18-19].  
System suitability 
The system suitability parameters were determined by preparing 
standard solutions of LP (36μg/ml) and SB (160 μg/ml). The 
solutions were injected six times and the parameters like peak 
tailing, resolution and USP plate count were determined. The % RSD 
for the area of six standard injections results should not be more 
than 2%. The results were shown in table 1.  
Specificity 
Specificity of a method was determined by testing standard substances 
against potential interferences. There should not be an occurrence of 
any interfering peaks in the blank and placebo at retention times of 
these drugs in this method. So this method was said to be specific.  
Linearity 
By appropriate aliquots of the standard LP and SB prepared six 
working solutions ranging between 9µg/ml to 54µg/ml and 4µg/ml 
to 240µg/ml. Each experiment linearity point was performed in 
triplicate according to optimized chromatographic conditions. 
Calibration curves were plotted with observed peak areas against 
concentration followed by the determination of regression equations 
and calculation of the correlation coefficient on curves for LP and SB. 
The results were shown in table 2.  
Accuracy 
Accuracy was carried out by % recovery studies of LP and SB at three 
different concentration levels (50%, 100%, and 150%). Percentage 
recovery was calculated from the amount added and the amount 
recovered. The percentage recovery was within the acceptance 
criteria, this indicates the accuracy of the method. (Acceptance criteria: 
% recovery between 98 to102). The results were shown in table 3.  
Precision 
The repeatability of the method was verified by calculating the % 
RSD of six replicate injections of 100% concentration (36 μg/ml of 
LP and 160 μg/ml of SB) on the same day and for intermediate 
precision % RSD was calculated from repeated studies on different 
days. The results were shown in table 4.  
Limit of detection (LOD) and limit of quantitation (LOQ) 
The LOD and LOQ were calculated by the use of equations LOD= 
3.3σ/S and LOQ=10σ/S where σ is the standard deviation of 
intercepts of calibration plots and S is the average of the slope of 
corresponding calibration plots. The results were shown in table 5.  
Robustness 
Robustness of the method was verified by altering the 
chromatographic conditions like flow rate, mobile phase ratio and 
temperature are made, but there was no recognized change in the 
result and all are within range as per ICH guidelines. Robustness 
conditions like flow minus (0.7 ml/min), flow plus (0.9 ml/min), 
Mobile phase ratio (Organic: Aqueous) minus 50:50, Mobile phase 
ratio (Organic: Aqueous) plus 60:40, temperature minus (25 °C) and 
temperature plus (35 °C) was maintained and samples were injected 
in a duplicate manner. System suitability parameter was passed. % 
RSD was within the limit. The result was shown in table 6.  
Degradation studies 
Acid degradation: To 1 ml of stock solution LP and SB, 1 ml of 2N 
hydrochloric acid was added and refluxed for 30 min at 60 °C. The 
resultant solution was diluted to obtain 36 μg/ml and 160 μg/ml 
solutions and 10 μl solutions were injected into the system and the 
chromatograms were recorded to assess the stability of the sample. 
The results were shown in fig. 8.  
Oxidative degradation 
To 1 ml of stock solution of LP and SB, 1 ml of 20% hydrogen 
peroxide (H2O2
Alkali degradation 
) was added separately. The solutions were kept for 
30 min at 60 °C. For HPLC study, the resultant solution was diluted 
to obtain 36 μg/ml and 160 μg/ml solution and 10 μl were injected 
into the system and the chromatograms were recorded to assess the 
stability of the sample. The results were shown in fig. 9.  
To 1 ml of stock solution Ledipasvir and sofosbuvir, 1 ml of 2N sodium 
hydroxide was added and refluxed for 30 min at 60 °C. The resultant 
solution was diluted to obtain 36μg/ml and 160μg/ml solution and 10 μl 
were injected into the system and the chromatograms were recorded to 
assess the stability of the sample. The results were shown in fig. 10.  
Thermal degradation 
The standard drug solution was placed in an oven at 105 °C for 6 h to 
study dry heat degradation. For HPLC study, the resultant solution 
was diluted to 36μg/ml and 160μg/ml solution and 10μl were 
injected into the system and the chromatograms were recorded to 
assess the stability of the sample. The results are shown in fig. 11.  
Photodegradation 
The photochemical stability of the drug was also studied by 
exposing the 360μg/ml and 1600μg/ml solution to uv-light by 
Reddy et al. 
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keeping the beaker in uv-chamber for 7 h or 200 Watt h/m2 RESULTS  in 
photostability chamber. For HPLC study, the resultant solution 
was diluted to obtain 36μg/ml and 160μg/ml solutions and 10 μl 
were injected into the system and the chromatograms were 
recorded to assess the stability of the sample. The results are 
shown in fig. 12.  
After a number of trials with mobile phases of different composition, 
and a mobile phase containing 0.1% orthophosphoric acid buffer at 
pH 2.2 and acetonitrile taken in the ratio of 45:55 v/v was selected 
as a mobile phase because of better resolution more number of 
theoretical plates and symmetric peaks. 
  
 
Fig. 3: Optimized chromatogram of ledipasvir and sofosbuvir 
 
System suitability 
According to ICH guidelines, plate count should be more than 2000, 
tailing factor should be less than 2 and resolution must be more than 
2. All the system suitable parameters were passed and were within 
the limits. 
Linearity 
A concentration range of 9-54 μg/ml for ledipasvir and 40-240 
μg/ml of sofosbuvir was found to be linear with correlation 
coefficients 0.999 were within limits. The result was shown in 
fig. 4 and 5. 
  
Table 1: System suitability parameters 
Parameter Ledipasvir Sofosbuvir 
Retention time (min) 2.246 3.502 
Theoretical plates (N) 3039 4771 
Tailing factor (T) 1.43 1.56 
 
 
Fig. 4: Calibration curve of sofosbuvir 
 
 
Fig. 5: Calibration curve of ledipasvir 
Reddy et al. 
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Table 2: Results for linearity 
Parameter  Ledipasvir  Sofosbuvir  
Y intercept  11373 16413 
Correlation coefficient r2  0.999  0.999  
Regression Equation  11373x+2351 16413x+2891 
Linearity range  9-54 μg/ml  40-240 μg/ml  
LOD  0.37 0.25  
LOQ  1.13  0.76  
 # n=6 i.e. number of samples for estimation 
 
Accuracy 
The percentage accuracy was a relative standard deviation (SD) for 
accuracy at each level is well within the limit. Overall the percentage 
recovery of the relative standard deviation was found to be 99.54%-
99.50 % for all the levels were within the limit. 
Precision 
Percentage relative standard deviation of six results was within the limit. 
Results shown good degree of precision was found to be 0.3% and 0.2%. 
Limit of detection 
Limit of detection of target assay concentration of ledipasvir and 
sofosbuvir by using formula method 0.37μg/ml and 0.25μg/ml 
within the limits. The results were shown in fig. 6. 
Limit of quantification 
Limit of quantification of the target assay concentration of 
Ledipasvir and sofosbuvir by using formula method 1.13μg/ml and 
0.76 μg/ml were within the limits. The results were shown in fig. 7. 
 















50% 18 17.94 99.64 80 79.62 99.52 
100% 36 35.83 99.52 160 159.28 99.55 
150% 54 53.71 99.47 240 238.59 99.41 
Mean recovery 99.54% Mean recovery 99.49% 
±SD 0.09 ±SD 0.07 
% RSD 0.09 % RSD 0.07 
#±SD: Standard deviation, # % RSD: Percentage relative standard deviation 
 
Table 4: Results of precision 
Drug Inter-day precision (%RSD) Method precision (% RSD) 
Ledipasvir 0.7 0.3 
Sofosbuvir 0.3 0.2 
 # n=6 i.e. number of injections, # % RSD: Percentage relative standard deviation 
 
 
Fig. 6: LOD of ledipasvir and sofosbuvir 
 
Table 5: Results for LOD and LOQ 
S. No. Drug  LOD (μg/ml)  LOQ (μg/ml)  
1 Ledipasvir 0.37 1.13 
2 Sofosbuvir 0.25 0.76 
 # LOD: Limit of detection, # LOQ: Limit of quantitation 
Reddy et al. 




Fig. 7: LOQ of ledipasvir and sofosbuvir 
 
Robustness 
Table 6: Result of robustness 
S. No. Condition Plus Minus 
1 Flow rate 0.9 ml/min 0.7 ml/min 
2 Mobile phase ratio (Organic: Aqueous) 60:40 50:50 
3 Column temperature 35 °C 25 °C 
In the above conditions the parameters like % RSD of peak area, tailing factor and theoretical plates showed were within the limit. 
 
Forced degradation study 
Degradation studies demonstrated the specificity of the developed 
method in the presence of degradation products. Degradation was 
carried out in combination of two drugs and purity of drug peaks 
was confirmed by purity angles. Their combination drug products 
were exposed to acid, alkali, oxidative and thermal stress conditions. 
Then found to be no degradable substances presence and proved 
that the proposed method was stable towards acid, alkali, peroxide 
and thermal conditions within the limits. 
 
Table 7: Results for stability studies of ledipasvir and sofosbuvir 
Degradation parameters   Stress condition % of degradation 
ledipasvir sofosbuvir 
Acid degradation  30 min refluxed with 2 N HCl at 60 °C 5.05 5.67 
Alkaline degradation  30 min refluxed with 2 N NaOH at 60 °C 4.43 3.93 
Peroxide degradation  30 min refluxed with 20% H2O2 3.66  at 60 °C 3.35 
Thermal degradation  6 h kept in dry oven at 105 ° C 2.99 2.67 
Photo degradation  UV light-254 nm for 7 h 1.83 1.70 
 
 
Fig. 8: Acid degradation 
Reddy et al. 




Fig. 9: Alkaline degradation 
 
 
Fig. 10: Peroxide degradation 
 
 
Fig. 11: Thermal degradation 
Reddy et al. 




Fig. 12: Photodegradation 
 
DISCUSSION 
For novel method development for simultaneous estimation of 
sofosbuvir and ledipasvir initially, various mobile phases and 
columns were tried to elute drug peaks with minimum tailing factor 
and more plate count were tried. For the developed method, Waters 
(2695) PDA detector HPLC using the software Empower 2 was 
selected, appreciable absorbance at 260 nm was determined 
spectro-photo metrically and hence it was selected as the detection 
wavelength. Then by using column discovery C8 250 mm x 4.6 mm, 5 
µm with mobile phase 0.1% opa buffer at pH 2.2 and acetonitrile in 
the ratio of 45:55 (v/v) by maintaining flow rate at 0.8 ml/min. 
Initially, prepared standard solution, sample solution and blank 
solution were injected and system suitability parameters were 
determined and listed in table 1 for both the drugs and the 
respective chromatograms were shown in fig. 3. The linearity graph 
for sofosbuvir and ledipasvir was plotted and shown in fig. 4 and fig. 
5 respectively, with the correlation coefficient of 0.999. The 
developed method was found to be accurate; the percentage 
recovery for sofosbuvir and ledipasvir was 99.49% and 99.54% 
respectively, data shown in table 3. The percentage RSD was found to 
be 0.3% and 0.7%, respectively, hence indicates that the method was 
precise. As there was no interference of retention time of placebo peak 
with drug peak, the method was found to be precise. Forced degradation 
studies for both the drugs revealed that both the drugs were stable 
during various applied stress conditions and the degradation for both 
drugs was found to be within limits as shown in table 7. The present 
developed method for simultaneous estimation of sofosbuvir and 
ledipasvir by rp hplc has been found to be the most innovative and novel 
as compared with other available literature. In most of the methods 
usually, a mixture of acetonitrile and water has been used as mobile 
phase with eclipse C18 column [20], whereas in present research 0.1% 
opa buffer is used with discovery C8 column and ultraviolet-visible 
detector (universal detector). In present work forced degradation study 
is also performed as compared with other work [15].  
CONCLUSION 
The present RP-HPLC developed and validated method allows a simple 
and rapid quantitative determination of ledipasvir and sofosbuvir in 
bulk and tablet dosage forms. All the validation parameters were 
found to be within the limits according to ICH guidelines. The 
proposed method was found to be specific for the drugs of interest 
irrespective of the excipients present and the short retention time 
allows the analyst to analyze various numbers of samples in a short 
period and method was found to be simple, accurate, precise, rugged, 
robust and stable under forced degradation stress conditions. So the 
established method can be successfully applied for the routine analysis 
of the marketed formulations. 
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